ArticleEuropean respiratory review : an official journal of the European Respiratory Society2023
Clinical-radiological-pathological correlation in pulmonary hypertension with unclear and/or multifactorial mechanisms.
Article in European respiratory review : an official journal of the European Respiratory Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 4 citations in OpenAlex.
- A case of rapidly progressive fatal pulmonary hypertension in a patient with metastatic bladder cancer: reflections on the early recognition of pulmonary tumour thrombotic microangiopathy.Journal of geriatric cardiology : JGC · 2025Article
- Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.Respiration; international review of thoracic diseases · 2025Review
- Sarcoidosis-associated pulmonary hypertension due to pulmonary arteries stenosis - a case report.BMC pulmonary medicine · 2024Article
- From the microscopic to the macroscopic: clinical-radiological-pathological correlation in pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ever since the second world symposium on pulmonary hypertension (PH) held in Evian, France, in 1998, PH has been classified into five major clinical groups. Group 5 PH includes a variety of distinct conditions with unclear and/or multifactorial underlying pathologies. Management of these patients is challenging as the number of patients within these groups is often small, not all individuals with certain underlying conditions are affected by PH and patients exhibit distinct symptoms due to different underlying diseases. Studies and clinical trials in these groups are largely lacking and mostly restricted to case series and registry reports. Nonetheless, the worldwide burden of group 5 PH is estimated to be significant in terms of the prevalence of some associated diseases. Group 5 PH encompasses six subgroups, including haematological disorders (inherited and acquired chronic haemolytic anaemia and chronic myeloproliferative disorders), systemic disorders (sarcoidosis, pulmonary Langerhans's cell histiocytosis and neurofibromatosis type 1), metabolic disorders (glycogen storage diseases and Gaucher disease), chronic renal failure with or without haemodialysis, pulmonary tumour thrombotic microangiopathy and fibrosing mediastinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.